Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK.

Context: Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia.

Objective: This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats.

Materials And Methods: Adult male Wistar rats (130 ± 10 g) were divided into 6 groups ( = 8 rats/group) as control, control + EA, control + EA + CC an AMPK inhibitor), T1DM, T1DM + EA, and T1DM + EA + CC.